We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2015 by National Institutes of Health Clinical Center (CC).
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00826241
First Posted: January 22, 2009
Last Update Posted: October 22, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
CERN Foundation - Collaborative Ependymoma Research Network
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC)
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Study Completion Date: No date given
  Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)

To Top